Dr. Roger Shapiro is a Professor of Immunology and Infectious Diseases at the Harvard TH Chan School of Public Health, a practicing Infectious Disease clinician, and Chair of the Board of Directors for the Botswana Harvard Health Partnership. Since 1999, he has worked in Botswana performing clinical trials to prevent vertical transmission of HIV and to reduce morbidity and mortality among children born to women living with HIV. Dr. Shapiro has been the principal investigator of NIH-funded studies to reduce HIV transmission during breastfeeding, to evaluate the impact of cotrimoxazole prophylaxis on childhood survival, and to study the impact of antiretroviral use in pregnancy on adverse birth outcomes. Since 2015, he has led a program to improve treatment outcomes among children living with HIV. This program includes the Early Infant Treatment Study, which follows a cohort of children started on antiretrovirals from birth; the Moso Study, which tests an optimized point-of-care diagnostic strategy at birth and early use of dolutegravir-based treatment; the Tatelo Study, which has evaluated two broadly neutralizing monoclonal antibodies (bNAbs) as alternate treatment for HIV; and the Tatelo Plus Study, which is currently evaluating three bNAbs as alternate treatment followed by an analytic treatment interruption in selected children.
